Antimicrobial susceptibility patterns of Ureaplasma species and Mycoplasma hominis in pregnant women

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Redelinghuys, Mathys J ^a   Ehlers, Marthie M ^a,b   Dreyer, Andries W ^a,b   Lombaard, Hennie A ^a   Kock, Marleen M ^a,b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Antimicrobial susceptibilities; Mycoplasma hominis; Pregnant women; Ureaplasma spp.

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOPLASMA HOMINIS; MYCOPLASMA HOMINIS INFECTION; PREGNANT WOMAN; SOUTH AFRICA; UREAPLASMA; UREAPLASMA INFECTION; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM; VAGINA SMEAR; ADULT; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOPLASMOSIS; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA HOMINIS; MYCOPLASMATALES INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UREAPLASMA;

EID: 84897508722     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-171     Document Type: Article

References (44)

1. Bayraktar MR, Ozerol IH, Gucluer N, Celik O. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women. Int J Infect Dis 2010, 14:e.90-e.95.
2. Razin S, Hayflick L. Highlights of mycoplasma research - an historical perspective. Biologicals 2010, 38:183-190. 10.1016/j.biologicals.2009.11.008, 20149687.
3. Stellrecht KA, Woron AM, Mishrik NG, Venezia RA. Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. J Clin Microbiol 2004, 42:1528-1533. 10.1128/JCM.42.4.1528-1533.2004, 387538, 15070999.
4. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, Yamada H, Sakuragi N, Minakami H. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol 2006, 44:51-55. 10.1128/JCM.44.1.51-55.2006, 1351938, 16390947.
5. Patel MA, Nyirjesy P. Role of Mycoplasma and Ureaplasma species in female lower genital tract infections. Curr Infect Dis Rep 2010, 12:417-422. 10.1007/s11908-010-0136-x, 21308549.
6. Zdrodowska-Stefanow B, Kłosowska WM, Ostaszewska-Puchalska I, Bułhak-Kozioł V, Kotowicz B. Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv Med Sci 2006, 51:250-253.
7. Kasprzykowska U, Elias J, Elias M, Maczyńska B, Sobieszczańska BM. Colonization of the lower urogenital tract with Ureaplasma parvum can cause asymptomatic infection of the upper reproductive system in women:a preliminary study. Arch Gynecol Obstet 2013, doi:10.1007/s00404-013-3102-7.
8. Rosemond A, Lanotte P, Watt S, Sauget AS, Gueriff F, Royere D, Goudeau A, Mereghetti L. Systematic screening tests for Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in urogenital specimens of infertile couples. Pathol Biol 2006, 54:125-129. 10.1016/j.patbio.2005.09.004, 16298086.
9. Kasper DC, Mechtler TP, Reischer GH, Witt A, Langgartner M, Pollak A, Herkner KR, Berger A. The bacterial load of Ureaplasma parvum in amniotic fluid is correlated with an increased intrauterine inflammatory response. Diagn Microbiol Infect Dis 2010, 67:117-121. 10.1016/j.diagmicrobio.2009.12.023, 20207094.
10. Dhawan B, Malhotra N, Sreenivas V, Rawre J, Khanna N, Chaudhry R, Mittal S. Ureaplasma serovars and their antimicrobial susceptibility in patients of infertility and genital tract infections. Indian J Med Res 2012, 136:991-996. 3612329, 23391795.
11. De Francesco MA, Negrini R, Pinsi G, Peroni L. Detection of Ureaplasma biovars and polymerase chain reaction-based subtyping of Ureaplasma parvum in women with or without symptoms of genital infections. Eur J Clin Microbiol Infect Dis 2009, 28:641-646. 10.1007/s10096-008-0687-z, 19130104.
12. Paralanov V, Lu J, Duffy LB, Crabb DM, Shrivastava S, Methé BA, Inman J, Yooseph S, Xiao L, Cassell GH, Waites KB, Glass JI. Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains. BMC Microbiol 2012, doi:10.1186/1471-2180-12-88.
13. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005, 18:757-789. 10.1128/CMR.18.4.757-789.2005, 1265909, 16223956.
14. Kechagia N, Bersimis S, Chatzipanagiotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicrob Chemother 2008, 62:122-125. 10.1093/jac/dkn158, 18424791.
15. Bébéar CM, Bébéar C. Antimycoplasmal agents. Molecular Biology and Pathogenicity of Mycoplasmas 2002, 545-566. London:Kluwer Academic/ Plenum Publishers, Razin S, Herrmann R.
16. Dongya M, Wencheng X, Xiaobo M, Lu W. Transition mutations in 23S rRNA account for acquired resistance to macrolides in Ureaplasma urealyticum. Microb Drug Resist 2008, 14:183-186. 10.1089/mdr.2008.0817, 18707551.
17. Xiao L, Crabb DM, Duffy LB, Paralanov V, Glass JI, Hamilos DL, Waites KB. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp. Int J Antimicrob Agents 2011, 37:377-379. 10.1016/j.ijantimicag.2010.12.012, 21353494.
18. Dégrange S, Renaudin H, Charron A, Bébéar C, Bébéar CM. Tetracycline Resistance in Ureaplasma spp. and Mycoplasma hominis:Prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates ofM. hominis susceptible to tetracyclines. Antimicrob Agents Chemother 2008, 52:742-744. 10.1128/AAC.00960-07, 2224736, 18025113.
19. Mardassi BBA, Aissani N, Moalla I, Dhahri D, Dridi A, Mlik B. Evidence for the predominance of a single tet(M) gene sequence type in tetracycline-resistant Ureaplasma parvum and Mycoplasma hominis isolates from Tunisian patients. J Med Microbiol 2012, 61:1254-1261. 10.1099/jmm.0.044016-0, 22580915.
20. Raynes-Greenow CH, Roberts CL, Bell JC, Peat B, Gilbert GL, Parker S. Antibiotics for Ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev 2011, 9:CD003767. doi:10.1002/14651858.CD003767.pub3.
21. Santos F, Sheehy O, Perreault S, Ferreira E, Bérard A. Trends in anti-infective drugs use during pregnancy. J Popul Ther Clin Pharmacol 2012, 19:e.460-e.465.
22. Koh E, Kim S, Kim I, Maeng K, Lee S. Antimicrobial susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis in pregnant women. Korean J Clin Microbiol 2009, 12:159-162.
23. Bébéar CM, Kempf I. Antimicrobial therapy and antimicrobial resistance. Mycoplasmas:Molecular biology, Pathogenicity and strategies for control 2005, 535-568. United Kingdom:Horizon Bioscience, Blanchard A, Browning GF.
24. Miller JM, Martin DH. Treatment of Chlamydia trachomatis infections in pregnant women. Drugs 2000, 60:597-605. 10.2165/00003495-200060030-00006, 11030469.
25. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy:a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007, 30:213-221. 10.1016/j.ijantimicag.2007.04.015, 17596917.
26. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001, 184:1352-1354. 10.1067/mob.2001.115050, 11408852.
27. Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM. Comparison of the new Mycofast Revolution assay with a molecular assay for the detection of genital mycoplasmas from clinical specimens. BMC Infect Dis 2013, 13:453. doi:10.1186/1471-2334-13-453, 10.1186/1471-2334-13-453, 3849776, 24079603.
28. Sá Del Fiol F, Gerenutti M, Groppo FC. Antibiotics and pregnancy. Pharmazie 2005, 60:483-493.
29. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis 2008, 47:33-43. 10.1086/588661, 18513147.
30. CLSI Methods for antimicrobial susceptibility testing for human mycoplasmas; Approved guideline. CLSI Document M43-A 2011, Wayne, PA:Clinical and Laboratory Standards Institute, CLSI.
31. Domingues D, Tavira LT, Duarte A, Sanca A, Prieto E, Exposto F. Genital mycoplasmas in women attending a family planning clinic in Guiné-Bissau and their susceptibility to antimicrobial agents. Acta Trop 2003, 86:19-24. 10.1016/S0001-706X(03)00002-0, 12711099.
32. Povlsen K, Thorsen P, Lind I. Relationship of Ureaplasma urealyticum biovars to the presence or absence of bacterial vaginosis in pregnant women and to the time of delivery. Eur J Clin Microbiol Infect Dis 2001, 20:65-67.
33. Govender S, Gqunta K, Le Roux M, De Villiers B, Chalkley LJ. Antibiotic susceptibilities and resistance genes of Ureaplasma parvum isolated in South Africa. J Antimicrob Chemother 2012, 67:2821-2824. 10.1093/jac/dks314, 22879459.
34. Zhu C, Liu J, Ling Y, Dong C, Wu T, Yu X, Hou Y, Dong L, Cheng X. Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases. Indian J Dermatol Venereol Leprol 2012, 78:406-407.
35. Ardic N, Oncul O, Ilga U, Turhan V, Haznedaroglu T, Ozyurt M. Investigation of the frequency and antibiotic susceptibility of Mycoplasma/Ureaplasma in urine samples with leukocyturia by different commercial methods. Internet J Infect Dis 2005, 4. doi:10.5580/df.
36. Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 2008, 282:147-159. 10.1111/j.1574-6968.2008.01145.x, 18399991.
37. Romoren M, Velauthapillai M, Rahman M, Sundby J, Klouman E, Hjortdahl P. Trichomoniasis and bacterial vaginosis in pregnancy:inadequately managed with the syndromic approach. Bull World Health Organ 2007, 85:297-304. 10.2471/BLT.06.031922, 2636319, 17546311.
38. White RG, Moodley P, McGrath N, Hosegood V, Zaba B, Herbst K, Newell M, Sturm WA, Hayes RJ. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect 2008, 84:528-534. 10.1136/sti.2008.032011, 2584238, 18708485.
39. Johnson LF, Dorrington RE, Bradshaw D, Coetzee DJ. The effect of syndromic management interventions on the prevalence of sexually transmitted infections in South Africa. Sex Reprod Healthc 2011, 2:13-20. 10.1016/j.srhc.2010.08.006, 21147454.
40. Lewis DA, Latif AS, Ndowa F. WHO global strategy for the prevention and control of sexually transmitted infections:time for action. Sex Transm Infect 2007, 83:508-509. 10.1136/sti.2007.028142, 2598641, 18024710.
41. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002, 156:647-650. 10.1001/archpedi.156.7.647, 12090829.
42. Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate:two case reports and a review of the literature. Pediatr Infect Dis J 1993, 12:688-691. 10.1097/00006454-199308000-00011, 8018130.
43. Howe E, Howe E, Benn RA. Hepatotoxicity due to erythromycin ethylsuccinate. Med J Aust 1993, 158:142-144.
44. Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical and rectal specimens for detection of Mycoplasma genitalium in women. J Clin Microbiol 2011, 49:1990-1992. 10.1128/JCM.00129-11, 3122633, 21411587.